Press Releases argenx SE Nasdaq

Equities

ARGX

US04016X1019

Market Closed - Nasdaq Other stock markets 01:30:00 21/05/2024 am IST			5-day change	1st Jan Change
361.6 ^USD	-1.16%		+0.58%	-4.95%

17/05	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	MT
15/05	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Argenx : argenx Reports First Quarter 2024 Financial Results and Provides Business Update	09/05	PU
Argenx Reports First Quarter 2024 Financial Results and Provides Business Update	09/05	GL
Argenx : argenx announces results of Annual General Meeting of Shareholders	08/05	PU
Argenx announces results of Annual General Meeting of Shareholders	08/05	GL
Argenx : argenx to Present at BofA Securities 2024 Health Care Conference	07/05	PU
Argenx to Present at BofA Securities 2024 Health Care Conference	07/05	GL
Argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024	02/05	GL
Argenx : argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	17/04	PU
Argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	16/04	GL
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	28/03	AQ
Argenx : argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	27/03	PU
Argenx : argenx Announces Annual General Meeting of Shareholders on May 7, 2024	27/03	PU
Argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	27/03	GL
Argenx Announces Annual General Meeting of Shareholders on May 7, 2024	27/03	GL
Argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia	26/03	GL
Argenx : argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	08/03	PU
Argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	08/03	GL
Argenx : argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update	01/03	PU
Argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update	29/02	GL
Argenx to Present at Upcoming Investor Conferences	26/02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases argenx SE Nasdaq

Equities

ARGX

US04016X1019

Press Releases

Filters